Table 2.
Outcomes of Jefferson two-step approach to allogeneic HSCT.
| Time to neutrophil engraftment (days) | Time to platelet engraftment (days) | WBC engraftment % | Platelet engraftment % | Grade II-IV GVHD | Grade III-IV GVHD | Chronic GVHD | Deaths from GVHD | Deaths from infection | Median CD3+/CD4+ count (cells/uL) | NRM | Rate of relapse | OS | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grosso et al., 2011 | 12 | 20.5 | 85%1 | 74%1 | 59% | 7% | 15% | None | 3 | 34 at 28 days, 105 at 100 days | 22% at 2 years | 32% at 2 years | 54% at 1 year, 48% at 3 years |
| Grosso et al., 2015 | 11 | 17 | 100% | 100% | 39% | 4% | 21% | None | None | 74 at 28 days, 148 at 90 days | 4% at 2 years | 21% at 2 years | 89% at 1 year, 77% at 2 years |
| Gaballa et al., 2016 | 11 (HI), 11 (MR) |
17 (HI), 18 (MR) | 96% (HI), 100% (MR) |
96% (HI), 100% (MR) |
40% (HI), 8% (MR) | 6% (HI), 4% (MR) | 19% (HI), 12% (MR) | None | 2 (HI), 0 (MR) |
50 (HI) and 48 (MR) at 28 days, 134 (HI) and 166 (MR) at 100 days | 10% (HI) and 4% (MR) at 3 years | 22% (HI) and 27% (MR) at 3 years | 70% (HI) and 71% (MR) at 3 years |
| Grosso et al., 2020 | 11 | 17 | 98% | 98% | 13% | 4% | 9% | None | None | 61 at 28 days, 177 at 90 days | 4% at 1 and 5 years | 31% at 2 years | 89% at 1 year, 66% at 5 years |
| Yang et al., 2022 | 11 | 16 | 100% | 100% | 45% | 5% | 15% | 42 | 62 | Not available | 30% at 3 years | 12% at 3 years | 63% at 3 years |
| Xia et al., 2022 | 11 | 18 | 100% | 100% | 39.5% | 11% | 19% | 4 | 16 | Not available | 43.5% at 3 years | 21% at 3 years | 37% at 3 years |
1Two multiparous female patients with multiple HLA donor-specific antibodies rejected grafts from their daughters. One of these patients received 4 doses of rituximab and apheresis then a reduced intensity conditioning regimen and achieved successful engraftment using the original donor.
2At extended follow-up of 6 years.
MR, matched-related.